Mitsubishi Tanabe Pharma has patented a method for treating inflammatory chronic diseases using a pharmaceutical composition with siRNA targeting the CHST15 gene. The treatment involves combining the composition with biological preparations inhibiting leukocyte tissue invasion or inflammatory cytokines, specifically for inflammatory bowel disease. GlobalData’s report on Mitsubishi Tanabe Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Mitsubishi Tanabe Pharma Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Mitsubishi Tanabe Pharma, was a key innovation area identified from patents. Mitsubishi Tanabe Pharma's grant share as of February 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment method for inflammatory chronic disease using sirna

Source: United States Patent and Trademark Office (USPTO). Credit: Mitsubishi Tanabe Pharma Corp

A recently granted patent (Publication Number: US11911409B2) discloses a method for treating chronic diseases, specifically inflammatory bowel disease, in patients in need. The method involves administering a pharmaceutical composition along with a biological preparation that inhibits leukocyte tissue invasion, inflammatory cytokines, or a combination of both. The pharmaceutical composition includes an active ingredient such as a siRNA that suppresses the expression of the CHST15 gene or a DNA vector expressing the siRNA. The biological preparations mentioned in the claims include Etrolizumab, Vedolizumab, Natalizumab, PF-00547659, and Vercirnon for inhibiting leukocyte tissue invasion, and antibodies targeting inflammatory cytokines like TNF-a, IL-17, IL-18, IL-23, IL-1p, and GM-CSF.

Furthermore, the method also involves administering additional treatments such as 5-aminosalicyclic acid preparations, steroid preparations, thiopurine preparations, and immunosuppressants like tacrolimus or cyclosporine in combination with the pharmaceutical composition and biological preparations. The administration can be done systemically or locally, with options for oral administration, intravenous injection, or submucosal administration into the intestine of the patient. The patent also covers the use of complexes for oral administration, including an active ingredient and N-acetylated chitosan, specifically targeting the suppression of the CHST15 gene for treating inflammatory bowel diseases like Crohn's disease or ulcerative colitis.

To know more about GlobalData’s detailed insights on Mitsubishi Tanabe Pharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies